Floatz logo

otx015

Glioblastoma Multiforme

Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 2Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
81/ 100

Competitive context

354 Active assets in the Glioblastoma Multiforme cohort.

Asset / SponsorPhaseRating
Irinotecan
Beijing Sanbo Brain Hospital
Phase 2/3BBB
Depatuxizumab Mafodotin
AbbVie
Phase 3BB
CARMUSTINE
Leland Metheny
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB
(+)-VINCRISTINE
University of Cincinnati
Phase 3BB

View all 50 →

Same molecule, other indications

otx015 is also rated in:

acute myeloid leukemiaDormant
C
Indicative ·
35 / 100
View asset →
diffuse large B-cell lymphomaDormant
C
Indicative ·
34 / 100
View asset →
nut midline carcinomaDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →